Navigation Links
Global Lung Cancer Therapeutics Market 2012-2016
Date:2/12/2013

NEW YORK, Feb. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Lung Cancer Therapeutics Market 2012-2016

http://www.reportlinker.com/p01095396/Global-Lung-Cancer-Therapeutics-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of MandAs. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG.

The other vendors mentioned in the report are

Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents 01. Executive Summary

02. Introduction

03. Market Coverage

Market Overview

Key Products

04. Market Landscape

Market Size

Market Forecast

04.1 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries

US

Germany

Japan

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis

15.1 Hoffmann-La Roche Ltd.

Business Overview

Key Information

SWOT Analysis

15.2 Eli Lilly and Co.

Business Overview

Key Information

SWOT Analysis

15.3 Sanofi S.A.

Business Overview

Key Information

SWOT Analysis

15.4 Bristol-Myers Squibb Co.

Business Overview

Key Information

SWOT Analysis

15.5 AstraZeneca plc

Business Overview

Key Information

SWOT Analysis

15.6 Novartis AG

Business Overview

Key Information

SWOT Analysis

15.7 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series

List of Exhibits: Exhibit 1: Global Lung Cancer Therapeutics Market 2012-2016 (US$ billion)

Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012

Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012

Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012

Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 6: Business Segmentation of Eli Lilly and Co.

Exhibit 7: Business Segmentation of Sanofi S.A.

Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 9: Business Segmentation of AstraZeneca plc

Exhibit 10: Business Segmentation of Novartis AG

Exhibit 11: Business Segmentation of GlaxoSmithKline plc

To order this report:Therapy Industry: Global Lung Cancer Therapeutics Market 2012-2016

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
2. Natalie Douglas, CEO of Idis, Joins Global Genes
3. RARE Project Board of Directors
4. Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes
5. RARE Project bei
6. Covance To Present At The Leerink Swann Global Healthcare Conference
7. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
10. Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
11. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
(Date:5/24/2016)... 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of sales, ... his new role, Marziani will lead the company,s business development and sales team, exploring ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... NJ (PRWEB) , ... May 25, 2016 , ... Researchers ... 2016 Annual COVD Meeting for their work on visual evoked potential and human attention. ... recent studies that used the Diopsys® NOVA™ ERG and VEP Vision Testing System ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article published ... randomly assigned to reduce the amount of calories they consumed by 25% experienced some ... weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared to ...
(Date:5/24/2016)... ... 2016 , ... PhishLine, the best-in-class, enterprise level security solutions ... President of Sales. Cifolelli’s primary responsibilities include management of the company’s sales ... field of organizational social engineering. , “We are delighted to have Rudy ...
Breaking Medicine News(10 mins):